Physician profile
Edward Prodanovic
NPI 1306067640
$9,663.96
in general payments reported to CMS, 2019-2025
29 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $23.77 · 2021: $72.56 · 2022: $1,869 · 2023: $2,949 · 2024: $3,035 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,097 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,097.41 |
| Education | $146.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.21 | 2019-2025 | |
| Janssen Biotech, INC. | $1,109.22 | 2022-2024 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $893.93 | 2021-2025 | Adbry |
| Ucb, INC. | $759.59 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $707.45 | 2022-2025 | |
| Incyte Corporation | $662.84 | 2022-2025 | Opzelura |
| Genzyme Corporation | $579.22 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $424.05 | 2020-2025 | Ilumya |
| Lilly USA, LLC | $411.54 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $408.59 | 2021-2025 | |
| Galderma Laboratories, L.P. | $351.74 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $346.42 | 2022-2025 | Libtayo, Dupixent |
| Amgen INC. | $277.90 | 2022-2025 | Otezla, Enbrel, Otezla |
| E.R. Squibb & Sons, L.L.C. | $246.87 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $223.02 | 2022-2024 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $201.50 | 2019 | |
| Janssen Scientific Affairs, LLC | $191.26 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $146.84 | 2023-2025 | Zoryve |
| Kyowa Kirin, INC. | $126.13 | 2022-2024 | Poteligeo |
| Argenx US, INC. | $108.02 | 2023 | Vyvgart |
| Botanix Sb INC | $38.83 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $31.31 | 2023 | Idacio |
| Mayne Pharma Commercial LLC | $30.47 | 2022 | |
| Krystal Biotech INC | $28.08 | 2023 | Vyjuvek |
| Biofrontera INC. | $21.60 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.19 | 2022 | |
| Almirall LLC | $18.16 | 2025 | Seysara |
| Biowound Solutions, INC. | $8.15 | 2025 | Bio-Connekt |
| Organon LLC | $5.83 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Prodanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.